KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Cash from Operations: 2019-2024

Historic Cash from Operations for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Dec 2024 value amounting to -$359.2 million.

  • Recursion Pharmaceuticals' Cash from Operations fell 98.16% to -$117.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$441.2 million, marking a year-over-year decrease of 38.81%. This contributed to the annual value of -$359.2 million for FY2024, which is 24.81% down from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Cash from Operations stood at -$359.2 million for FY2024, which was down 24.81% from -$287.8 million recorded in FY2023.
  • In the past 5 years, Recursion Pharmaceuticals' Cash from Operations ranged from a high of -$45.4 million in FY2020 and a low of -$359.2 million during FY2024.
  • In the last 3 years, Recursion Pharmaceuticals' Cash from Operations had a median value of -$287.8 million in 2023 and averaged -$243.5 million.
  • In the last 5 years, Recursion Pharmaceuticals' Cash from Operations plummeted by 249.38% in 2021 and then spiked by 47.34% in 2022.
  • Over the past 5 years, Recursion Pharmaceuticals' Cash from Operations (Yearly) stood at -$45.4 million in 2020, then tumbled by 249.38% to -$158.6 million in 2021, then surged by 47.34% to -$83.5 million in 2022, then crashed by 244.55% to -$287.8 million in 2023, then dropped by 24.81% to -$359.2 million in 2024.